Sort
15,273 grants matching “antimicrobial resistance”
Collectins and Innate Defense against Inhaled Pathogens
$945,582Barbara A Seaton · Boston University Medical Campus · P01 · FY2009 · AI
Development of novel proteins synthesis inhibitors for MDR tuberculosis
$945,212Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2012 · AI
NSF Convergence Accelerator - Track D: Data-Driven Disease Control and Prevention in Veterinary Health
$944,875Beatriz Martinez Lopez · University Of California-Davis · · FY2020 · TIP
Efficacy of Tympanostomy Tubes for Children with Recurrent Acute Otitis Media
$942,929Alejandro Hoberman · University Of Pittsburgh At Pittsburgh · U01 · FY2016 · DC
Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance
$941,497Alehandro Hoberman · University Of Pittsburgh At Pittsburgh · N01 · FY2015 · AI
Expanding small molecule functional metagenomics through shuttle BAC expression i
$941,322Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2014 · AI
RNA: New Antimicrobial Strategies
$941,172Adrian Ferre-D'amare · National Heart, Lung, And Blood Institute · ZIA · FY2013 · HL
Development of novel proteins synthesis inhibitors for MDR tuberculosis
$940,979Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2011 · AI
IAS 2025. the 13th IAS Conference on HIV Science, Kigali, Rwanda, 14-17 July 2025
$940,000Chris Beyrer · Ias · R13 · FY2025 · AI
Pathogenic differences between Cryptococcus neoformans and C. gattii
$939,657Kyung Kwon-Chung · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Rapid phage-amplified immunoassay for phenotypic UTI diagnosis and antimicrobial susceptibility testing
$939,582Christopher R Cox · Cobio Diagnostics Inc. · R44 · FY2022 · DK
Sialic acid analogs against multidrug-resistant gonorrhea
$936,377Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · AI
Sialic acid analogs against multidrug-resistant gonorrhea
$935,587Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AI
THE USE OF ANTIMICROBIALS IN FOOD ANIMALS CONTINUES TO CAUSE CONCERN REGARDING DEVELOPMENT OF ANTIMICROBIAL RESISTANCE (AMR). THERE IS LITTLE DATA ON AMR DEVELOPMENT IN SMALL RUMINANTS. DATA SUGGESTS THAT MOST DAIRY GOATS HAVE AN INTRAMAMMARY INFECTION AT DRY-OFF. WITHOUT TREATMENT, MOST OF THESE INFECTIONS PERSIST INTO THE FOLLOWING LACTATION. ALMOST NO EVIDENCE-BASED DATA EXISTS TO INFORM THE DEVELOPMENT OF EFFECTIVE ANTIBIOTIC STEWARDSHIP RECOMMENDATIONS AND EDUCATIONAL CAMPAIGNS TOWARDS DAIRY GOATS. OUR GOAL IS TO IMPROVE GOAT MILK QUALITY THROUGH PRUDENT TREATMENT PROGRAMS THAT MAINTAIN FOOD SAFETY, AND TO DISSEMINATE AN EXTENSION PROGRAM TO STAKEHOLDERS. THE CENTRAL HYPOTHESIS IS THAT APPLICATION OF APPROACHES DEMONSTRATED TO BENEFIT ANTIMICROBIAL STEWARDSHIP AND MINIMIZE AMR DEVELOPMENT IN DAIRY CATTLE CAN BE EFFECTIVE IN GOATS. WE WILL ATTAIN THE OVERALL GOAL VIA THESE OBJECTIVES:1. DETERMINE THE ANTIMICROBIAL RESIDUE DEPLETION PROFILE IN MILK AND MEAT OF GOATS FOLLOWING ADMINISTRATION OF DRY COW INTRAMAMMARY ANTIMICROBIALS.2. UTILIZING A SELECTIVE APPROACH, DETERMINE THE EFFICACY OF DRY-OFF ANTIMICROBIAL PRODUCTS AGAINST INTRAMAMMARY INFECTIONS.3. DETERMINE WHETHER ADMINISTRATION OF DRY COW ANTIMICROBIALS RESULTS IN THE DEVELOPMENT OF ANTIMICROBIAL RESISTANCE IN DAIRY GOATS.4. DEVELOP A COMPREHENSIVE EXTENSION PROGRAM THAT DEMONSTRATES HOW ESTABLISHED MASTITIS PREVENTION STRATEGIES, COUPLED WITH A JUDICIOUS ANTIMICROBIAL APPROACH, CAN MINIMIZE ANTIMICROBIAL RESISTANCE AND PRESERVE FOOD SAFETY. WE WILL OBTAIN OUR GOALS THROUGH A SEQUENTIAL SERIES OF TRIALS THAT FOLLOW THE ABOVE OBJECTIVES, CULMINATING WITH A COMPREHENSIVE, SUSTAINABLE EXTENSION PROGRAM THAT PROVIDES DAIRY GOAT PRODUCERS WITH RESOURCES FOR EFFICACIOUS ANTIMICROBIAL USE THAT MINIMIZES AMR AND PRESERVES FOOD SAFETY.
$933,567Iowa State University Of Science And Technology · · FY2021 · National Institute of Food and Agriculture
RNA: New Antimicrobial Strategies
$933,275Adrian Ferre-D'amare · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa
$932,445George Louis Drusano · University Of Florida · R01 · FY2019 · AI
Discovery of Natural Products and Natural Product-Like Inhibitors
$931,691Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Discovery, Structural Studies and Biosynthesis of Biologically Active Natural Products and Natural Product-Like Inhibitors
$931,691Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Discovery of Natural Products and Natural Product-Like Inhibitors
$931,690Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
A High Throughput Biofilm Assay System
$929,976Cristian Ionescu-Zanetti · Fluxion Biosciences, Inc. · R44 · FY2009 · GM
Sialic acid analogs against multidrug-resistant gonorrhea
$928,732Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · AI
An immunotherapeutic to prevent gonorrhea
$928,633Keith Wycoff · Planet Biotechnology, Inc. · R44 · FY2021 · AI
Photochemical Generation of Gas Phase Nitric Oxide from Immobilized S-Nitrosothiols for Biomedical Applications
$928,479Alexander Keith Wolf · Nota Laboratories, Llc · R44 · FY2022 · HL
Molecular mechanisms of immune evasion in Staphylococcus aureus
$928,200Michael Otto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
A systems approach to manipulate microbial adaptation to structured environments
$927,560Nitin S Baliga · Institute For Systems Biology · R01 · FY2019 · AI